71125-38-7 Usage
Description
Meloxicam, also known as Mobic, is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the oxicam class. It is a selective inhibitor of cyclooxygenase-2 (COX-2) and is primarily used for the management of rheumatoid arthritis and osteoarthritis. Meloxicam is effective in reducing pain, inflammation, swelling, and stiffness of the joints. It has a relatively long half-life of 15 to 20 hours and is associated with a lower rate of serious gastrointestinal side effects and a lower risk of nephropathy compared to other conventional NSAIDs. Meloxicam is metabolized in humans mainly by the CYP2C9 enzyme system, with a minor contribution from CYP3A4.
Uses
1. Used in Pharmaceutical Industry:
Meloxicam is used as an anti-inflammatory agent for the symptomatic treatment of arthritis and osteoarthritis. It functions by inhibiting prostaglandin synthetase (cyclooxygenase 1 and 2), leading to a decrease in the synthesis of prostaglandins, which are chemicals that contribute to inflammation, particularly within joints.
2. Used in Pharmaceutical Industry as a Preferential COX-2 Inhibitor:
Meloxicam is used as a preferential cyclooxygenase (COX-2) inhibitor, which results in an improved gastrointestinal safety profile compared to other NSAIDs such as naproxen, diclofenac, and prioxicam.
3. Used in Pharmaceutical Industry as an Angiotensin 2 Receptor Antagonist:
Meloxicam is also used as an angiotensin 2 receptor antagonist, which may contribute to its anti-inflammatory effects.
4. Used in Veterinary Medicine:
Meloxicam formulations have been used in the treatment of osteoarthritis and rheumatoid arthritis in animals, such as in a canine model of unilateral osteoarthritis of the right stifle joint.
5. Used in Ophthalmology:
Meloxicam (0.03%) has been shown to reduce croton oil-induced increases in TNF-α and IL-1β mRNA levels and increase IL-10 mRNA levels in the cornea in a rabbit model of acute ocular inflammation.
References
https://en.wikipedia.org/wiki/Meloxicam
https://www.drugbank.ca/drugs/DB00814
https://www.drugs.com/meloxicam.html
http://www.medicinenet.com/meloxicam/article.htm
Indications
Meloxicam (Mobic), recently introduced for the
treatment of osteoarthritis, is also used for rheumatoid
arthritis and certain acute conditions. Although meloxicam
is sometimes reported to be a selective COX-2 inhibitor,
it is considerably less selective than celecoxib or
rofecoxib. Its adverse effects are similar to those of
piroxicam and other NSAIDs; however, the frequency
of GI side effects is lower for meloxicam than for piroxicam
and several other NSAIDs.
Manufacturing Process
A mixture of 26.9 g (0.1 mol) of the 1,1-dioxide of methyl 4-hydroxy-2- methyl-2H-1,2-benzothiazine-3-carboxylate and 12.5 g (0.11 mol) of 2- amino-5-methylthiazole was refluxed in 4 liters of xylene for 24 hours in a nitrogen atmosphere. The methanol formed by the reaction was removed by means of a 4-A-molecular sieve mounted in a Soxhlet-extractor. The hot reaction solution was filtered. Upon cooling and standing overnight, the crude product separated out of the filtrate in the form of crystals (32.0 g, 91% of theory). After recrystallization from ethylene chloride 26.0 g (74% of theory) of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3- carboxamide-1,1-dioxide were obtained; M.P.: 254°C (decomp.).
Therapeutic Function
Antiinflammatory
Clinical Use
In April 2000, the U.S. FDA approved meloxicam for the treatment of osteoarthritis. When meloxicam was initially introduced in the United Kingdom, it was promoted as a selective COX-2 inhibitor.
Veterinary Drugs and Treatments
Meloxicam is principally used for the symptomatic treatment of osteoarthritis
in dogs. Short-term (single dose injectable) use is also
approved (in the USA) for cats for the control of postoperative pain
and inflammation associated with orthopedic surgery, ovariohysterectomy
and castration when administered prior to surgery.
Metabolism
Meloxicam, however, is less
selective than celecoxib and much less selective than rofecoxib in in vitro studies.
Meloxicam is readily absorbed when administered orally and is highly bound to plasma proteins. Meloxicam is
extensively metabolized in the liver, primarily by CYP2C9 and, to a lesser extent, by CYP3A4. The advantages of
meloxicam over celecoxib and rofecoxib in the treatment of osteoarthritis (or rheumatoid arthritis) are not readily
apparent.
Check Digit Verification of cas no
The CAS Registry Mumber 71125-38-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,1,2 and 5 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 71125-38:
(7*7)+(6*1)+(5*1)+(4*2)+(3*5)+(2*3)+(1*8)=97
97 % 10 = 7
So 71125-38-7 is a valid CAS Registry Number.
71125-38-7Relevant articles and documents
Manufacture of high-purity meloxicam via its novel potassium salt monohydrate
Mezei, Tibor,Mesterhazy, Norbert,Bako, Tibor,Porcs-Makkay, Marta,Simig, Gyula,Volk, Balazs
, p. 567 - 572 (2009)
An improved procedure for the manufacture of 4-hydroxy-2- methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (meloxicam) is described. The key intermediate of this protocol is the new potassium salt monohydrate of meloxicam, which makes possible the efficient removal of impurities, resulting in an environmentally friendly manufacturing process of the high-purity (>99.90%) drug substance.
Process for the Purification of Meloxicam
-
Page/Page column 2, (2008/12/05)
A process for purifying meloxicam form I from a crude meloxicam, which comprises: i. contacting the crude meloxicam with an amine in a non-aqueous solvent to form a meloxicam salt;ii. isolating the meloxicam salt;iii. dissolving the meloxicam salt in an aqueous solvent to form a salt solution; andiv. adding an acid to the salt solution to precipitate free meloxicam.
Process for the purification of meloxicam
-
Page/Page column 5, (2008/06/13)
Process for the purification of meloxicam and in particular of the impurity composed of 4-hydroxy-2-methyl-N-ethyl-N'-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide comprising the following steps: a) the meloxicam is treated in crude form with an alcohol solution of an alkaline alcoholate at a temperature between 25 and 35°C.b) the solution obtained in step (a) is acidified to a pH between 1.5 and 4.0 and the precipitated product composed of meloxicam is filtered, the wet filtered product obtained from the previous step is crushed in a polar aprotic solvent and the product of the crushing is isolated by means of filtration and drying.
